How it works
It's highly selective for MC1R — the pigmentation receptor — with minimal activity at the MC3R/MC4R receptors that cause melanotan II's central effects. This selectivity is why it could become an approved product.
The evidence
Approval rests on clinical trials in EPP showing it lets patients tolerate more light exposure. That's a narrow, specific indication — not a general tanning approval.
Safety
Generally well tolerated in its approved use; reported effects include injection-site reactions, nausea, fatigue, dizziness, and headache, with rare concerns like new moles/skin lesions warranting monitoring. It's a prescription implant, not a research chemical.
FAQ
No — it's approved only for a rare medical condition (EPP), as a prescription implant. Cosmetic tanning isn't its approved use.
Afamelanotide (I) is selective and approved for EPP; melanotan II is non-selective, unapproved, and riskier.
Sources
This profile summarizes the following. Follow the links to read the originals — and remember that summaries age, so check for newer information.
Inclusion here is not endorsement of any source's claims; several are cited so you can compare how different outlets characterize the same evidence.
Reviewed by Remy — part of the PepConnection crew.